mefloquine plus artesunate

DRUG3 trials

Sponsors

Centers for Disease Control and Prevention, Medicines for Malaria Venture, London School of Hygiene and Tropical Medicine

Conditions

Falciparum MalariaMalariaMalaria FalciparumSickle Cell Crisis

Phase 1

Intermittent Preventive Treatment for Malaria in Patient With Sickle Cell Disease

CompletedNCT01319448

London School of Hygiene and Tropical MedicineMalaria, Sickle Cell Crisis

Start: 2011-09-30End: 2013-04-30Updated: 2014-03-21

Phase 3

Pyronaridine - Artesunate (3:1) Versus Mefloquine Plus Artesunate in Plasmodium Falciparum Malaria Patients

CompletedNCT00403260

Medicines for Malaria VentureFalciparum Malaria

Start: 2007-01-31End: 2008-12-31Updated: 2021-11-02

Unknown Phase

Efficacy and Effectiveness of Combined Therapy for Uncomplicated Malaria Treatment in Peru

CompletedNCT00164216

Centers for Disease Control and PreventionMalaria Falciparum

Start: 2005-03-31End: 2008-03-31Updated: 2012-09-11

Related Papers

Population Pharmacokinetics of Pyronaridine in Pediatric Malaria Patients

Antimicrobial Agents and Chemotherapy2015-12-1536 citations

A Randomized Trial to Compare the Safety, Tolerability, and Effectiveness of 3 Antimalarial Regimens for the Prevention of Malaria in Nigerian Patients With Sickle Cell Disease

The Journal of Infectious Diseases2015-02-2018 citations

Safety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials.

2013-02-2158 citations

Pyronaridine-artesunate versus mefloquine plus artesunate for malaria.

2012-04-0167 citations